Every industrial process produces heat. In many cases, that heat is useful, up to a point, after which, it becomes waste. Too low in temperature to be reused efficiently, too difficult to capture, and often simply released. For Green52’s Wim Essing, that overlooked category of energy is exactly where the opportunity lies.

With a background in automotive engineering, engine tuning and high-performance technology, Essing has spent most of his career pushing technical systems to their limits. “I’ve always been fascinated by the physical boundaries of technology”, he says. That curiosity led him to a striking physical anomaly in a specific temperature range. By using that anomaly, Essing has developed a thermodynamic generator that can convert low-grade waste heat into electricity. The first prototype is running. Now the challenge is to turn a promising proof of concept into a scalable technology.

Recovering lost energy

The idea behind the machine is simple to explain, but technically complex to realise. Many industrial processes generate heat at temperatures that are too low for existing conversion technologies. Above roughly 200 degrees Celsius, there are established ways to use heat to generate power. Below that point, the options become much more limited.

Essing’s technology is designed for exactly that lower temperature range. “I put 60-degree heat in, and create electricity. It’s a unique solution”, he says. In its current form, the prototype can use a temperature difference, for example cooling water from 60 to 40 degrees Celsius, to activate the anomaly in the material. That creates pressure, which can then be converted into electricity.

The prototype has run and has been independently assessed, but it is still far from a commercial product. The current machine weighs around 5,500 kilos and produces only about 1,000 watts. The next question is whether it can be engineered into something smaller, stronger, cheaper and durable for industrial use.

From prototype to industrial application

The potential applications are broad: data centers, aluminum foundries, food processing plants, power stations and large industrial sites all produce heat that is often removed through air or water cooling and then lost.

Essing imagines a future in which that heat forms the basis for renewed electricity.  “This is essentially ‘free’ electricity. Of course, there’s the costs of the machine, turning the question into: how long does it operate, and what is the return on investment?”

The prototype has proven the technical principle to work, but the stresses inside the machine are high. Components are exposed to significant forces, and the team now needs to understand how materials behave over time. “We now have to find out how long the system can keep running under these conditions”, Essing says. Which parts can be bought off-shelf?  Where is custom engineering needed?

And what level of efficiency is good enough for a commercially viable machine? The environmental benefit may be obvious, but for industry, calculations must also work financially. Essing is clear that perfection is not the goal in the first commercial version. “If we do not recover 50 percent of the waste heat, but perhaps 30 percent, that may still be highly valuable”, he says.

The funding gap between invention and scale

So far, the development has been funded by a group of five private investors. Together, they have put over a million euros into the prototype. The next step is significantly larger. To move from proof of concept to industrial technology, Essing expects that several million euros will be needed for research, engineering, modelling, durability testing and team development.

That makes the project challenging for traditional angel investment. The potential impact is large, but the road to market is long and technically risky. During the BANN session, Essing pitched Green52 to a group of business angels, to learn how investors viewed the opportunity.

What BANN and Briskr brought

The direct investment result was straightforward: zero. Yet the session was far from a disappointment. “Why would you not invest in this?” Essing asked the investors during the conversations. Their answers were honest and insightful. The technology is not yet proven durably. The return on investment is too uncertain at this stage.

For Essing and his investors, that feedback helped sharpen the next step. The project  may be very suitable for public funding, European innovation programmes or subsidy routes focused on sustainable energy, energy efficiency and grid congestion.

The BANN programme helped Essing present the technology to experienced investors and advisers. “It was a very positive experience for me”, he describes. “The support in preparing the pitch was really good.” The process helped him understand what investors still need before stepping in, and several people offered to help explore subsidy opportunities.

Keeping the opportunity in the Netherlands

The ambition is high. At the same time, Essing is realistic. The technology is still at an early readiness level. For now, the company is looking for the right route to continue development. That may involve subsidies, universities and technical partners. To move forward, the company needs people who can help build the organisation around the invention: subsidy specialists, technical partners, business developers and eventually a broader engineering team.

And eventually, it needs larger investors. Essing’s preference is clear: he wants the intellectual property and the opportunity to stay in the Netherlands for as long as possible. “But not at all costs, because if we really put a team of people on this, I believe we can make something beautiful”, he says.

Foto: Chris Smits

De verkiezing StartUpper van het Jaar 2026 is dé kans voor ambitieuze startups in het Rijk van Nijmegen om zich te laten zien. StartUp Nijmegen gaat opnieuw op zoek naar de startup die het verschil maakt. Ben jij een ondernemer die barst van de ideeën én actie onderneemt? Dan is dit jouw moment om in de spotlight te staan.

Wat is de StartUpper van het Jaar?

Met de verkiezing van de StartUpper van het Jaar 2026 zetten we innovatieve en veelbelovende startups uit de regio in de schijnwerpers. Ondernemers krijgen de kans om hun verhaal te vertellen, hun netwerk uit te breiden en hun onderneming onder de aandacht te brengen van een deskundige jury en een breed publiek.

De verkiezing is bedoeld voor startups die al de eerste stappen hebben gezet en klaar zijn om verder te groeien. Naast de eer van de titel biedt deelname ook waardevolle exposure, nieuwe contacten en de mogelijkheid om jouw onderneming op een groter podium te presenteren.

Voorwaarden voor deelname aan de StartUpper van het Jaar 2026

Om deel te nemen aan de verkiezing van de StartUpper van het Jaar 2026 moet jouw onderneming aan de volgende voorwaarden voldoen:

  • De onderneming mag niet vóór 30 oktober 2021 zijn ingeschreven bij de Kamer van Koophandel.
  • De onderneming is gevestigd in één van de zeven gemeenten van het Rijk van Nijmegen: Beuningen, Berg en Dal, Druten, Heumen, Mook en Middelaar, Nijmegen of Wijchen.
  • Het bedrijf maakt omzet.

Hoe werkt de verkiezing van de StartUpper van het Jaar?

Stap 1 – Aanmelden

Meld jezelf of een andere ondernemer aan via het aanmeldformulier. Ken jij een ondernemer die volgens jou de titel StartUpper van het Jaar 2026 verdient? Dan kun je deze persoon ook voordragen.

Stap 2 – Selectie

Uit alle aanmeldingen selecteren we een aantal veelbelovende startups die worden uitgenodigd voor de voorrondes. Tijdens deze ronde pitch je jouw onderneming aan een deskundige jury en krijg je de kans om te laten zien waarom jouw startup het verschil maakt.

Stap 3 – Finale

Drie geselecteerde kandidaten gaan door naar de grote finaleavond op donderdag 29 oktober 2026. Tijdens dit evenement staan jij en je onderneming écht in de schijnwerpers. Je maakt kans op fantastische prijzen, waardevolle contacten en volop exposure voor jouw bedrijf.

Waarom deelnemen aan de StartUpper van het Jaar?

Deelname aan de StartUpper van het Jaar 2026 is meer dan alleen een verkiezing. Het is een kans om:

  • Jouw onderneming onder de aandacht te brengen van een breed publiek.
  • In contact te komen met andere ondernemers en experts uit de regio.
  • Waardevolle feedback te ontvangen van een ervaren jury.
  • Je netwerk uit te breiden en nieuwe kansen te creëren.
  • Extra zichtbaarheid te krijgen voor jouw startup.

Aanmelden voor StartUpper van het jaar 2026

Klik hier om naar het aanmeldformulier te gaan

The Radboudumc Investmentday 2026 is coming up!
On October 7, researchers, entrepreneurs and investors from across the Life Sciences & Health ecosystem will come together for a day focused on meaningful connections, knowledge sharing and new opportunities at the Radboudumc Experience Center.

Are you developing an innovative startup in Life Sciences, MedTech, or another healthcare-related field? This is your opportunity to connect with investors who are actively looking for promising innovations, explore future collaborations and expand your network.

One of the highlights of the day is the dedicated matchmaking programme, allowing participants to schedule one-on-one meetings in advance and make the most of every conversation.

The Radboudumc Investmentday is jointly organised by Radboudumc, Briskr, Oost NL and Radboud University, bringing together the region’s leading innovation ecosystem to accelerate the future of healthcare.

Interested in joining as a startup or researcher? We’d love to hear from you. Please contact marion.schouten@briskr.nl for more information or find out more on the website.

There is more to intellectual property (IP) than meets the eye. Overlooking the hidden parts can put your IP at risk. In biotech, investors are keen to see a robust IP strategy. Patented technology justifies the substantial investments needed to bring new medicines through the regulatory pipeline. An IP strategy also signals your professionalism as an entrepreneur. Taking IP seriously from the start gives you a big advantage.

The helpful employee

Let’s have a look at four examples to show what could go wrong. The first concerns a fictional biotech firm with 40 employees and an open culture built on trust. A client calls the receptionist and asks for the technical drawings of one of the company’s products. However, these drawings are a trade secret. There is no policy in place. The receptionist has access to the drawings and, wanting to be helpful, shares them without requesting a signed non-disclosure agreement (NDA). The client uses the drawings to develop their own version of the product and markets it aggressively. The result? In court, the company faces an uphill battle and may not be able to prove it treated the drawings as a trade secret at all.


When collaboration goes sour

The second example concerns an early-stage start-up that aims to collaborate with a contract research organization (CRO). They have clear agreements in place on foreground IP (the IP that results from the collaboration). All other details are covered by the CRO’s standard collaboration contract. The start-up brings forward many new ideas and suggestions during the collaboration. However, none of these are in writing. At one of their meetings, the CRO informs the start-up that it will file for a patent. The start-up claims that the patent is inspired by their ideas and suggestions. According to the CRO, it further developed the ideas that were brought into the collaboration. As far as the CRO is concerned, the invention is its own. Without written evidence of the start-up’s contributions, the CRO’s position is difficult to challenge. The start-up has lost any claim to inventorship, as well as any share of what may become a valuable patent.


Freedom to operate

In the third example, a biotech company has multiple lines of research and expects to enter the market soon with a new innovation. The company has already announced its new product and the techniques used in production at two high-profile conferences. Shortly afterwards, a letter arrives from a competitor’s lawyer: the new product infringes on a patent application filed by the competitor. The company is forced to postpone the product release until it can negotiate a licence fee with the competitor – assuming the competitor is willing to grant one. By announcing the product and technology publicly, the company alerted a rival who might otherwise not have noticed the overlap. The underlying failure is that the company thought of a freedom-to-operate analysis before investing in the launch.


Going public and the novelty requirement

In the final example, a university spin-off developed a novel medical product. There is a lot of interest in the start-up, prompting it to give interviews and product presentations. The company is explicitly asked to demonstrate its new product, so the audience can appreciate its innovative qualities. At the same time, the company is looking for investors to help bring the product to the market. As IP is a key concern for potential investors, the company wants to file a patent. One of the core requirements for a patent is novelty. But the company already disclosed its product publicly. Now it is wrestling with the novelty requirement: only parts of the invention that were not shown, if any, can still form the basis of a patent filing. The result is a narrower patent at best, no patent at all at worst. For a company built on investor confidence, that is a serious problem: weak IP weakens the pitch, and no IP can end the conversation entirely.

Take IP seriously

The above examples share a common thread: overlooking IP during product development can be costly. Seemingly small omissions like an undocumented conversation or a presentation given too soon can lead to loss of IP, or lost investors. None of these failures are difficult to prevent. It starts with taking IP seriously from day one.

The Netherlands Patent Office is happy to help you. They offer free 1-on-1 consult with a patent advisor: a useful starting point for building an IP strategy.

About the Netherlands Patent Office

The Netherlands Patent Office helps entrepreneurs who want to protect their innovation, find collaboration partners, or secure funding. Whether you are a start-up, scale-up or SME, our support is confidential, independent and free of charge. From walk-in advice sessions at tech hubs to tailored patent search advice: our advisors work across the country to support you.

Bringing an innovative medical device to market is about much more than developing great technology. Understanding the regulatory landscape early on can save valuable time, reduce risks and help you make better strategic decisions throughout your product development journey.

In this practical workshop, regulatory experts from Qserve will guide you through the key differences and similarities between the European and US regulatory pathways for medical devices. Through practical examples, you’ll gain insight into how your product is classified, what evidence is required and how to plan your route to market.

During the second part of the workshop, participants will split into two smaller groups, allowing for more in-depth discussions tailored to their specific technology. Depending on the participating startups, the sessions will focus on either software and AI-based medical devices or non-active patient-contacting and higher-risk medical devices.

Whether you are still validating your idea or preparing for market entry, this workshop will help you better understand the regulatory and clinical considerations that can influence your development strategy.

What will you learn?

  • The different market access routes for medical devices in the EU and the US
  • How to determine whether your product qualifies as a medical device
  • Medical device classification in both regulatory systems
  • What clinical and technical evidence is required
  • How to estimate regulatory timelines, costs and development planning

Speakers

Robert Paassen, Team Manager Regulatory Medical Devices & Senior Consultant | Qserve

Robert has extensive experience in regulatory affairs for medical devices and supports innovative companies in developing efficient regulatory strategies for both European and international markets. During this workshop, he will explain the regulatory fundamentals and help startups understand the key decisions they need to make early in product development.

Additional specialist sessions

To ensure participants receive the most relevant insights, a second Qserve expert will join the workshop based on the technologies represented by the participating startups. Depending on the biggest ask it will be either Coenraad or Bianca:

Coenraad Davidsdochter, Team Manager Regulatory Medical Devices & Senior Consultant

Coenraad specializes in software, AI-based and active medical devices and supports companies in navigating the regulatory requirements for these rapidly evolving technologies.

Bianca Lutters, Director Knowledge Management, Head of Clinical Affairs & Principal Consultant.

Bianca specializes in clinical strategy, implantable and higher-risk medical devices, combining extensive regulatory expertise with deep knowledge of clinical evaluation and evidence generation.

Location
Meet&Greet, Noviotech Campus Nijmegen.

Good to know
The workshop is facilitated in English and is free of charge.

Participation in the workshop is free for everyone, including drinks and bites. However, for noshow and cancellations within 24 hours prior to the event, we will charge a fee of 15 euros (excluding VAT) to cover incurred expenses. By signing up, you agree to this term.

Are you developing a new method, technology, product, software tool, or creative work? Then it’s important to understand how intellectual property (IP) works. Especially if you want to protect your work or explore its potential beyond the academic context. 

This masterclass provides a clear introduction to IP, tailored to researchers and early-stage entrepreneurs at Radboud University. You’ll learn what types of IP exist – including patents, copyrights, and design rights – and how they apply to research, inventions, software, games, products, and other creative outputs. 

We’ll explain who owns what if you are and employee of e.g. the Radboud University and what to consider if you’re thinking about publishing, sharing, or commercializing your work. 

The session includes a presentation by RVO and offers space for questions about your specific situation. 

What we’ll cover 

– how open science relates to intellectual property
– different types of intellectual property, including patents and copyrights 
– how IP applies to software, tools, games, products, and creative work 
– who owns the IP
– why IP matters in research, education, and entrepreneurship
– how to protect your idea and when to act
– where to find support or advice 

This masterclass is for

– researchers and early-stage entrepreneurs
– anyone considering how to share, publish, or apply their work outside academia 

More info and sign up here.

Monthly IP walk-in for health & hightech entrepreneurs. Are you a startup or SME in the health or hightech sector? Every month, we host a free walk-in session where you can get expert advice on Intellectual Property (IP).

Why IP matters

As an entrepreneur, protecting your ideas, technologies, and brand is crucial. Whether you’re developing medical innovations, software, or high-tech devices, having a solid IP strategy can help you secure funding, attract partners, and stay ahead of the competition. From patents and trademarks to design rights and trade secrets—knowing your options can make all the difference.

Meet Rienk Rienksma – IP Advisor at RVO

Rienk is an Intellectual Property advisor at the Netherlands Patent Office. The Netherlands Patent Office is the official body responsible for granting patents in the Netherlands. It supports startups and SMEs with questions about IP rights in the broadest sense—whether it’s patent protection, trademarks, or understanding how to safeguard your innovation roadmap.

The advice is confidential, free of charge, and completely independent—no commercial interests involved.

You’re welcome to just walk in, or if you prefer, you can make an appointment in advance.

Contact Rienk Rienksma: rienk.rienksma@rvo.nl

Afgelopen dinsdag kwamen startups,  challengehouders en een team van experts en projectpartners samen voor de eerste gezamenlijke sessie van het Digital Health Challenge Lab.

Het Digital Health Challenge Lab is een samenwerking van Briskr, Oost NL, HAN en Health Valley, waarin we verkennen hoe challenge-based innoveren kan bijdragen aan betere en snellere innovatie in de gezondheidszorg.

Tijdens de bijeenkomst maakten de deelnemers kennis met elkaar, pitchten zij hun plannen en gingen zij in gesprek met experts (Jarik Bijlsma, Daniel ten holder, Geert Frederix) die met scherpe vragen en feedback hielpen om ideeën verder te brengen.  Een belangrijke les van de dag: innovatie draait niet alleen om een groot einddoel, maar vooral om het zetten van de juiste stap op het juiste moment. De eerste trede van de ladder richting impact.

Ook stond samenwerking centraal. Welke kennis, vaardigheden en rollen zijn binnen een startup aanwezig? Zijn de hacker, hustler en hipster vertegenwoordigd? En hoe kunnen startups, challengehouders en experts elkaar versterken om samen die stap verder te zetten?

Op 7 juli komen we opnieuw bijeen. Dan bouwen we verder op de opgedane inzichten, delen we weer ervaringen en zetten we samen de volgende stappen richting concrete oplossingen. Mooi om te zien hoeveel energie, kennis en ambitie er in de groep aanwezig is. Op naar de volgende bijeenkomst!

Master the Art of Pitching with International Coach David Beckett!

Back by popular demand, this workshop is your opportunity to learn the secrets of crafting a winning pitch from one of the best in the business. David Beckett, an internationally renowned pitch coach, has helped over 2.500 startups and scaleups secure more than €460 million in funding. Now, he’s ready to help you sharpen your pitch skills in a dynamic, hands-on session.

In this fast-paced workshop, you’ll dive into practical techniques to build a compelling storyline, make your message clear and unforgettable, and deliver a powerful opening and closing. With fun, interactive exercises, you’ll practice each step and gain confidence in presenting your pitch with impact.

Plus, you’ll leave with exclusive resources and access to David’s Pitch App, designed to help you perfect your pitch long after the workshop ends. Whether you’re preparing a pitch for investors, clients, or networking events, this is your chance to stand out and make a lasting impression.

Don’t miss this chance to elevate your pitch game and join a community of ambitious professionals!

Afterwards, you’ll receive a selection of materials and access to an App that will help you deliver your winning pitch, handshake pitch and/or elevator pitch! 

David Beckett Bio

David Beckett is an International Pitch Coach, who has trained over 2900 Startups and Scaleups to win over €490Million in investment. He’s also trained more than 41,000 professionals at companies such as Vodafone, Tommy Hilfiger, PwC and AirFrance KLM, in 33 countries – as well as over 30 TEDx speakers. David is the creator of The Pitch Canvas©, and author of the books Pitch To Win and Long Story Short.

LinkedIn: https://www.linkedin.com/in/davidbeckettpresentationcoach/

Location
Meet&Greet, Noviotech Campus Nijmegen.

Good to know
The workshop is facilitated in English and is free of charge and organised together with The Launch.

Participation in the workshop is free for everyone, including drinks and bites. However, for noshow and cancellations within 24 hours prior to the event, we will charge a fee of 15 euros (excluding VAT) to cover incurred expenses.

Wat was het vorige week weer een mooie editie van het Business Angels Network Nijmegen (BANN).

Op Slot Doddendael presenteerden Baseboard, Green52, Picard Systems en Metal Minds hun plannen aan een zaal vol investeerders. Vier verschillende bedrijven, vier sterke verhalen en volop aanleiding voor interessante gesprekken.

Met pitches uit verschillende sectoren en ontwikkelfases bood de avond een mooie mix van innovaties, markten en groeikansen. Juist die diversiteit zorgde voor waardevolle discussies en maakte de bijeenkomst interessant voor een breed netwerk van investeerders.

Toch zit de kracht van BANN niet alleen in de pitches. Het zijn juist de ontmoetingen tussen ondernemers en investeerders die deze bijeenkomsten bijzonder maken. Na de pitches en Q&A rondes werden tijdens de borrel en het diner nieuwe contacten gelegd, ervaringen gedeeld en mogelijkheden verkend voor de toekomst. Met enthousiaste ondernemers, betrokken investeerders, heerlijk eten en een uitstekende sfeer kijken we terug op een zeer geslaagde bijeenkomst.

Dank aan iedereen die erbij was en aan onze partners die BANN mede mogelijk maken: naast Briskr ook: Oost NL, BDO, EP&C, Qserve Group, Johnson&Johnson, Rabobank, The Economic Board Arnhem-Nijmegen en Gemeente Nijmegen.

We kijken uit naar de vervolggesprekken en zijn benieuwd welke mooie samenwerkingen en investeringen uit deze ontmoetingen zullen ontstaan. Op 10 november vindt de volgende BANN-bijeenkomst plaats.

Fotograaf: Linda Verweij